{"id":"W3120695991","doi":"10.1097/md.0000000000023677","title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (“ProDERM Study”)","year":2021,"lang":"en","type":"article","venue":"Medicine","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Mallinckrodt Pharmaceuticals; CSL Behring; Genentech; AstraZeneca; Alexion Pharmaceuticals; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Dermatomyositis; Tolerability; Placebo; Adverse effect; Randomized controlled trial; Clinical endpoint; Internal medicine; Clinical trial; Placebo-controlled study; Surgery; Physical therapy; Double blind; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00268714,0.0004617886,0.003134064,0.000388371,0.0001749348,0.00002354309,0.0001086298,0.000109645,0.0003960916],"category_scores_gemma":[0.0008352297,0.0003049497,0.0001079068,0.0006746801,0.0003191198,0.0001522798,0.0001171976,0.0004364762,0.000004964876],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001141422,"about_ca_system_score_gemma":0.0002493603,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009590651,"about_ca_topic_score_gemma":0.00007765675,"domain_scores_codex":[0.9951544,0.0007422027,0.00172427,0.0006991699,0.001250237,0.0004297436],"domain_scores_gemma":[0.9969727,0.0007251819,0.0005347338,0.0006164908,0.0009216169,0.0002292138],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7829766,0.004944191,0.1982669,0.0001697106,0.0007776922,0.0007598167,0.009983714,0.00001138812,0.00007351317,0.00002402071,0.00005952509,0.001952988],"study_design_scores_gemma":[0.8672895,0.005684255,0.1182764,0.0007739518,0.001557609,0.00009590723,0.005407994,0.0004196813,0.0002201803,0.000009092005,0.00001675614,0.0002486918],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9794153,0.0006877783,0.00006614802,0.0004512542,0.0001342281,0.01747367,0.000005558235,0.00006074487,0.001705294],"genre_scores_gemma":[0.99838,0.0000258775,0.0001594876,0.0001623611,0.0001366013,0.000741802,0.00006072506,0.00005122236,0.0002819191],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08431297,"threshold_uncertainty_score":0.9999403,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01772533112619751,"score_gpt":0.3242649747962098,"score_spread":0.3065396436700123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}